Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study

Current Medical Research and Opinion

Volumn 16, Issue 2, 2000, Pages 80-87

  Ose, Leiv ^a   Luurila, Olavi ^b   Eriksson, J ^c   Olsson, Anders ^d   Lithell, Hans ^e   Widgren, Bengt ^f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Lääkäriasema Koe Oy   (Finland)

^c Health Centre of Seinäjoki   (Finland)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerivastatin; Efficacy; Gender; Hypercholesterolaemia

Indexed keywords

CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FINLAND; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORWAY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SWEDEN;

EID: 0033936873     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079900542876     Document Type: Article

References (8)

1. Ose, L., Luurila, O., Eriksson, J., Olsson, A., Lithell, H. and Widgren, B., on behalf of the Cerivastatin Study Group (1999). Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Curr. Med. Res. Opinion, 15, 228-240.
2. Stein, E. A., Schopen, U. and Catagay, M. (1999). A pooled efficacy analysis of cerivastatin in the tretament of primary hyperlipidaemia. Clin. Drug Invest., 18, 433-444.
3. Geil, P. B., Anderson, J. W. and Gustafson, N. J. (1995). Women and men with hypercholesterolaemia respond similarly to an American Heart Association Step I Diet. J. Am. Dietet. Assoc., 95, 436-446.
4. Assman, G., Schulte, H., von Eckardstein, A. and Huang, Y. (1996). High-density lipoprotein as a predictor for coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 124 (Suppl), S11-S20.
5. International Task Force for the Prevention of Coronary Heart Disease (1998). Coronary heart disease: reducing the risk. Nutr. Metab. Cardiovasc. Dis., 8, 205-271.
6. NCEP Adult Treatment Panel II Report (1993). J. Am. Med. Assoc., 269, 3015-3023.
7. Jones, P., Kafonek, S., Laurora, I. and Hunninghake, D. (1998). Comparative dose-efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol., 81, 582-587.
8. Vaughan, C., Gotto, A. and Basson, C. (2000). The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol., 35, 1-10.